Boston Scientific (NYSE:BSX) Sets New 1-Year Low Following Analyst Downgrade

Shares of Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The stock traded as low as $65.20 and last traded at $64.4060, with a volume of 451819 shares trading hands. The stock had previously closed at $69.17.

Other equities analysts also recently issued research reports about the stock. Oppenheimer reduced their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Morgan Stanley dropped their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Wells Fargo & Company cut their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, TD Cowen decreased their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.36.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.34% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Asurys fluid management system gives Boston Scientific another regulatory win and supports growth in perioperative/OR product offerings. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Strong HI-PEITHO trial results for the EKOS endovascular system (positive readout reported) bolster the company’s pulmonary embolism franchise and provide clinical momentum for EKOS adoption. Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
• Positive Sentiment: Several analysts reaffirm buy/outperform ratings and high price targets (Needham, TD Cowen, RBC), reflecting confidence in long-term growth drivers like Watchman FLX and diversified product mix. Buy Rating on Boston Scientific’s Watchman FLX
• Neutral Sentiment: Company set an investors’ conference call for the Q1 2026 results (April 22), which will be a key event for management to clarify guidance, procedure trends and margin outlook. Boston Scientific announces conference call
• Neutral Sentiment: Analysts expect single-digit EPS growth for Q1 2026; Q1 results and any guidance update will likely drive near-term volatility but may not change the long-term thesis. Boston Scientific’s Q1 2026 Earnings: What to Expect
• Negative Sentiment: Mixed/underwhelming clinical data for the Watchman device (conflicting trial readouts) is the proximate trigger for today’s sell-off as investors reprice stroke-prevention growth expectations. Boston Scientific Falls After Underwhelming Trial Results
• Negative Sentiment: Raymond James downgraded BSX and cut its price target, and Goldman trimmed its target as well — analyst downgrades and lower PTs pressured sentiment and valuation multiples. Shares Plunge After Raymond James Downgrade
• Negative Sentiment: Heightened legal/regulatory overhang — multiple investor alerts and class-action filings tied to prior disclosures are creating uncertainty and may keep pressure on the stock until resolved. BSX Investor Alert: Securities Fraud Lawsuit

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Steph & Co. bought a new position in shares of Boston Scientific in the third quarter valued at approximately $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Finally, Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter worth $26,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market cap of $93.49 billion, a price-to-earnings ratio of 32.42, a price-to-earnings-growth ratio of 1.07 and a beta of 0.69. The company has a fifty day moving average price of $76.94 and a two-hundred day moving average price of $90.32.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the business posted $0.70 earnings per share. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.